Table 1.
Summary of clinical trials involving AI/ML and pancreatic cancer.
| Trial ID | Location | Study | Study Start Date | Enrollment |
|---|---|---|---|---|
| NCT04743479 | Shanghai, China | ESPRIT-AI | 20 December 2020 | 5000 |
| NCT03452774 | New York, NY, USA | SYNERGY-AI | 1 January 2018 | 50,000 |
| NCT06055010 | Utrecht, The Netherlands | IMPACT | 1 January 2014 | 5000 |
| NCT06320717 | Buffalo, NY, USA | AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma | 2 January 2024 | 100 |
| NCT04899739 | Strasbourg, France | EchoSurg | 5 December 2021 | 45 |
| NCT06256705 | Clichy, France | OPERANDI-NET | 25 March 2024 | 80 |
| NCT05729737 | Beijing, China | Radiographic Response to Chemotherapy in Unresected Localized Pancreatic Cancer | 1 January 2022 | 100 |